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The transcription factor NFAT5 limits
infection-induced type I interferon responses
Hector Huerga Encabo1, Laia Traveset1, Jordi Argilaguet2, Ana Angulo3, Estanislao Nistal-Villán4, Rahul Jaiswal5, Carlos R. Escalante5,
Christos Gekas6, Andreas Meyerhans2,7, Jose Aramburu1, and Cristina López-Rodŕıguez1
Type I interferon (IFN-I) provides effective antiviral immunity but can exacerbate harmful inflammatory reactions and cause
hematopoietic stem cell (HSC) exhaustion; therefore, IFN-I expression must be tightly controlled. While signaling mechanisms
that limit IFN-I induction and function have been extensively studied, less is known about transcriptional repressors acting
directly on IFN-I regulatory regions. We show that NFAT5, an activator of macrophage pro-inflammatory responses, represses
Toll-like receptor 3 and virus-induced expression of IFN-I in macrophages and dendritic cells. Mice lacking NFAT5 exhibit
increased IFN-I production and better control of viral burden upon LCMV infection but show exacerbated HSC activation
under systemic poly(I:C)-induced inflammation. We identify IFNβ as a primary target repressed by NFAT5, which opposes the
master IFN-I inducer IRF3 by binding to an evolutionarily conserved sequence in the IFNB1 enhanceosome that overlaps a key
IRF site. These findings illustrate how IFN-I responses are balanced by simultaneously opposing transcription factors.
Introduction
The involvement of type I IFN (IFN-I) in promoting diverse
immunopathologies highlights the need for understanding
mechanisms that repress its expression. However, while signal
transductionmechanisms that limit IFN-I production or function
are quite well characterized, less is known about transcription
repressors that control IFN-I genes by acting directly on their
genomic regulatory regions (Arimoto et al., 2018; Levy et al.,
2011), and few direct repressors, such as activating transcrip-
tion factor 3 (ATF3; Labzin et al., 2015) and IFN regulatory factor
2 (IRF2; Senger et al., 2000), have been studied in detail. IFN-I
plays a central role in the protection against pathogens such as
viruses (McNab et al., 2015; Ivashkiv and Donlin, 2014) but is also
a potent driver of autoinflammatory and autoimmune diseases.
Exacerbated inflammatory responses can damage tissues, en-
hance activation of pattern-recognition receptors (PRRs), and
lead to increased and persistent IFN-I production (Rodero and
Crow, 2016; Theofilopoulos et al., 2005). The physiopathological
role of IFN-I extends to other scenarios such as the exhaustion of
adaptive immune responses during chronic viral infections, the
control of tumor progression, and the activation of hematopoi-
etic stem cells (HSCs) in response to inflammatory stress (King
and Goodell, 2011; Zitvogel et al., 2015; Snell and Brooks, 2015).
IFN-I comprises IFNβ, different forms of IFNα, and other IFN
types (Pestka et al., 2004), all of which can be expressed in re-
sponse to PRRs such as particular transmembrane TLRs and
cytosolic RNA and DNA sensors (Akira et al., 2006; Wu and
Chen, 2014) that detect molecular patterns from pathogens
and damaged cells. IFN-I signals through the IFNα/β receptor
(IFNAR) to induce the expression of numerous IFN-stimulated
genes (ISGs), encoding proteins that modulate the viral life cycle
or work as positive and negative regulators of the response to
IFN-I (MacMicking, 2012; Schneider et al., 2014). Expression of
IFN-I is orchestrated by diverse transcription regulators, among
which IRF3, IRF7, and p65/NF-κB are the key factors that rec-
ognize the regulatory regions of IFN-I genes and induce their
expression upon PRR activation in cells such as conventional and
plasmacytoid dendritic cells (pDCs), macrophages, and fibro-
blasts (McNab et al., 2015; Ivashkiv and Donlin, 2014; Honda
et al., 2006). Transcription of Ifnb1 is the best-characterized
paradigm for IFN-I induction, with a short promoter region
containing a central 50-bp element known as the IFNβ enhan-
ceosome, which is recognized by IRF3, IRF7, and p65/NF-κB
(Panne et al., 2007). In parallel to the characterization of tran-
scriptional activators of IFN-I, studies have identified numerous
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negative regulators that act on PRR-regulated signaling com-
ponents and also downstream IFNAR (Arimoto et al., 2018),
underscoring the importance of a tight control of IFN-I re-
sponses to prevent their potentially pathogenic effects. In this
context, though, our knowledge about transcription regulators
that could directly repress IFN-I expression is still quite limited
(Arimoto et al., 2018; Levy et al., 2011; Ivashkiv and Donlin,
2014).
NFAT5 is a transcription factor of the Rel family with ho-
mology to NF-κB and calcineurin-activated NFATc proteins.
NFAT5 modulates diverse immune functions in myeloid cells
and lymphocytes in basal conditions and in response to pathogen
receptors, cytokines, and hypertonic stress (Aramburu and
López-Rodŕıguez, 2019). NFAT5 is constitutively expressed in
macrophages and is further induced and activated by TLR
through the IKKβ–NF-κB pathway to promote expression of
diverse pro-inflammatory genes (Buxadé et al., 2012; Aramburu
and López-Rodŕıguez, 2019). This function of NFAT5, which can
be enhanced by hypertonic stress, supports the classical polar-
ization of macrophages and also protects against Leishmania
infection in vivo (Buxadé et al., 2012; Jantsch et al., 2015;
Tellechea et al., 2018). While NFAT5 can be inducibly recruited
to promoters of target genes, such as Nos2 and Il6 upon TLR
activation, it can also be constitutively bound to regulatory re-
gions of other genes in basal conditions as shown for the master
MHCII regulatory factor Ciita (Buxadé et al., 2012, 2018). PRR
activation induces many types of gene products in addition to
prototypical inflammatory cytokines, and receptors such as
TLR3 also induce IFN-I expression (Akira et al., 2006; Wu and
Chen, 2014). In this work, we report that NFAT5 represses IFN-I
transcription, and thus attenuates IFN-I–dependent responses,
and identify IFNβ transcription as a primary target for NFAT5.
We found that NFAT5 binds the Ifnb1 enhanceosome in a TLR3-
dependent manner to prevent IRF3 binding and inhibit IFNβ
promoter activity. Expression of IFN-I and ISG was amplified in
NFAT5-deficient macrophages, DCs, and fibroblasts upon viral
infection or direct TLR3 stimulation with poly(I:C) (polyino-
sinic-polycytidylic acid). NFAT5-deficient mouse models reacted
to poly(I:C)-induced systemic inflammation with increased IFN-
I–mediated activation of their HSCs, and responded to viral in-
fection with enhanced stimulation of the IFN-I pathway and
improved control of viral load.
Results
NFAT5 inhibits TLR3-induced IFN-I responses in macrophages
and DCs
Previous work has shown that NFAT5 induces diverse pro-
inflammatory genes in response to TLRs and classical macro-
phage polarization (Buxadé et al., 2012; Tellechea et al., 2018).
Gene set enrichment analysis (GSEA) of a previously published
NFAT5-regulated transcriptome in macrophages stimulated
with the TLR4 ligand LPS (Buxadé et al., 2012) identified en-
hanced expression of ISGs in NFAT5-deficient macrophages
(Fig. 1 A, bottom). Intrigued by this finding, we explored the
potential contribution of NFAT5 to IFN-I responses in macro-
phages stimulated with poly(I:C), a synthetic double-strand RNA
that activates endosomal TLR3 when added directly to the
culture medium. TLR3 engages the TRIF adaptor-dependent
signaling pathway and induces robust IFN-I expression by ac-
tivating p65/NF-κB, IRF3, and IRF7 (O’Neill and Bowie, 2007;
Oshiumi et al., 2003; Yamamoto et al., 2003). GSEA of micro-
array experiments with poly(I:C)-treated, NFAT5-deficient bone
marrow–derived macrophages (BMDMs) revealed a global up-
regulation of IFN-I response genes with respect to wild-type
BMDMs (Fig. 1 A, top), but not other TLR3-regulated responses
such as the apoptosis gene set (Fig. S1 A). Macrophages did not
display any NFAT5-sensitive IFN-I response in the absence of
poly(I:C) stimulation (Fig. 1 A, middle). The GSEA also identified
an enhanced IFNγ (type II IFN) signature in poly(I:C)-treated,
NFAT5-deficient BMDMs, consistent with the similar gene ex-
pression patterns shared by type I and II IFN responses (Fig. S1
A). Almost half of the genes differentially expressed between
poly(I:C)-treated NFAT5-deficient and wild-type macrophages
(1,209 out of 2,731) were annotated in the Interferome database
as responsive to IFN-I (Interferome database v2.01; Rusinova
et al., 2013), and from these, 62% were upregulated in NFAT5-
deficient cells (Fig. 1 B, Fig. S1 B, and Table S1). Lack of NFAT5
did not affect the expression of diverse genes encoding for
components of the TLR3 signaling pathway (Tlr3 itself, Ticam1/
Trif1, Traf3, Traf6, Ripk1, Tbk1, Ikbke, Irf3, and Irf7, among others)
or the IFN-I receptor (Ifnar1, Ifnar2, Jak1, and Jak2, among others)
in macrophages stimulated with poly(I:C) (Table S2). Altogether,
the analysis of these RNA datasets revealed an unexpected du-
ality in the function of NFAT5, since in addition to facilitating
expression of prototypical pro-inflammatory genes upon TLR
stimulation (Buxadé et al., 2012), it could also restrain IFN-I
responses.
We next used real-time quantitative PCR (RT-qPCR) to
compare the expression of Ifnb1 and various ISGs in BMDMs,
bone marrow–derived DCs (BMDCs), and freshly isolated peri-
toneal macrophages and observed that lack of NFAT5 caused a
significant increase in the induction of these genes in the three
populations upon poly(I:C) treatment (Fig. 1, C and D), indicating
a widespread role for NFAT5 in limiting IFN-I responses. We
also analyzed NFAT5-deficient macrophages for their response
to IFNα (IFNα4) and Pam3CSK, a TLR2 agonist that induces
NFAT5 expression and activation (Buxadé et al., 2012), but does
not induce IFN-I responses in macrophages. Compared with the
NFAT5-inhibited Ifnb1, Ifna1, Ifna7, and ISG (Ifit2 and Mx1) ex-
pression upon poly(I:C) stimulation, induction of these genes by
IFNαwas not repressed by NFAT5, and Pam3CSK did not induce
them (Fig. 1 E). Similarly, IFNβ-induced robust expression of
ISGs and modest induction of IFN-I genes in macrophages were
independent of NFAT5 (Fig. 1 F). In line with these findings,
poly(I:C) treatment in vivo caused exacerbated Ifnb1 expression
in peritoneal macrophages (CD11b+ cells) of mice lacking NFAT5
in immune cells (Nfat5fl/fl Vav-Cre; Fig. 1 G). NFAT5-deficient
BMDMs also produced significantly more IFNβ protein in re-
sponse to poly(I:C) (Fig. 1 H), and this was associated with in-
creased phosphorylation and upregulation of STAT1 upon IFNAR
activation (Fig. 1 I and Fig. S1 E). However, we did not detect
obvious differences between wild-type and NFAT5-deficient
BMDMs in TLR3-induced phosphorylation of IRF3, the master
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regulator of IFN-I transcription (Fig. 1 I). NFAT5 itself accu-
mulated in macrophages upon prolonged poly(I:C) treatment
but not by direct IFN-I (IFNα4 or IFNβ) stimulation (Fig. 1, E
and F; and Fig. S1 C; Buxadé et al., 2012), and indeed, TLR3-
induced NFAT5 accumulation was IFNAR-independent (Fig.
S1 D). Altogether, this set of results showed that NFAT5 re-
pressed IFN-I expression in macrophages and DCs activated
by TLR3, but not upon direct stimulation with IFN-I, which
suggested that NFAT5 acted upon TLR3 activation but not
upon direct IFNAR activation.
Enhanced IFN-I production and viral clearance upon
lymphocytic choriomeningitis virus (LCMV) infection in mice
lacking NFAT5
In view of these results, we asked about the biological impact of
NFAT5 on IFN-I responses during a viral infection in vivo. We
assessed this in a mouse model of infection with LCMV, a single-
stranded RNA virus that activates different TLR and cytosolic
RNA sensors (Borrow et al., 2010). C57BL/6 mice infected with a
low dose of LCMV strain Docile developed a self-resolving acute
infection that starts to be controlled around day 9 (Moskophidis
et al., 1993). This infection model causes a rapid and transient
burst of IFN-I that is required to control viral replication, prime
virus-specific CD8+ T lymphocytes, and prevent their exhaus-
tion (Merigan et al., 1977; Cousens et al., 1999; Borrow et al.,
2010; Ng et al., 2013). We therefore sought to analyze the early
phase of the response to acute viral infection in mice lacking
NFAT5 in immune cells (Nfat5fl/fl Vav-Cre) using a low dose (2 ×
102 PFU per mouse) of the LCMV strain Docile. Compared with
control littermates, Nfat5fl/fl Vav-Cre mice showed enhanced
levels of IFNα in serum 2 d after infection (Fig. 2 A) and im-
proved control of their viral load (Fig. 2 B). Analysis of spleen
pDCs (CD11c+ B220+; Fig. 2 C and Fig. S2 A), peritoneal mac-
rophages (CD11b+; Fig. 2 D), and bone marrow pDCs (CD11c+
B220+) and macrophages (CD11b+ F4/80+; Fig. S2, B–D) iso-
lated 2–3 d after infection showed increased expression of
Ifnb1 and different ISGs in Nfat5fl/fl Vav-Cre mice, together
with reduced expression of the LCMV nucleoprotein gene
(LCMV NP). In parallel, we confirmed that percentages of pDCs
and macrophages were similar in spleens and bone marrow of
infected Nfat5fl/fl Vav-Cre and control mice (Fig. S2 E). We
next used myeloid-specific NFAT5-deficient mice (Nfat5fl/fl
LysM-Cre) to avoid a potential contribution of NFAT5 in T
lymphocytes (Alberdi et al., 2017) when analyzing a later time
point after acute LCMV infection. These mice also presented
increased IFNα production 2 d after infection (Fig. 2 E) and
maintained better clearance of their viral load in spleen and
peritoneal macrophages 5 d later (Fig. 2, F and G), at the peak
of viral burden and when IFN-I is nearly undetectable
(Moskophidis et al., 1993; Merigan et al., 1977; Borrow et al.,
2010). Therefore, these acute infection experiments showed
that lack of NFAT5 in macrophages and pDCs enhanced IFN-I
production and improved viral clearance in vivo.
NFAT5 represses IFN-I responses in macrophages and DCs
infected with different viruses
We next asked whether NFAT5 could control the IFN-I pathway
upon direct infection of DCs and macrophages by viruses that
have different functional characteristics and activate different
PRRs. First, we observed that macrophages infected with ve-
sicular stomatitis virus (VSV) or murine CMV (MCMV) accu-
mulated Nfat5 mRNA, which reached a maximal expression at
24 h (Fig. 3 A, left panels). Analysis of the response of NFAT5-
deficient macrophages (BMDMs) and GM-CSF–induced con-
ventional bone marrow–derived myeloid DCs (GM-BMDCs) to
VSV orMCMV showed that they expressed higher levels of Ifnb1,
Ifit2, and Mx1 compared with control cells coinciding with the
peak of the response 12 h after infection (Fig. 3, A and B). Sim-
ilarly, NFAT5-deficient Flt3 ligand (Flt3L)–induced conventional
(CD11c+ CD11b+) and plasmacytoid (CD11c+ B220+) BMDCs re-
sponded to VSV or LCMV infection with increased expression of
different IFN-I genes (Ifnb1, Ifna1, and Ifna7) and Ifit2 (Fig. 3 C and
Figure 1. NFAT5 inhibits TLR3-induced IFN-I responses in macrophages and DCs. (A) GSEA of Hallmark database for the IFNα response from microarray
data comparing wild-type (Nfat5+/+, WT) and NFAT5-deficient (Nfat5−/−, knockout [KO]) BMDMs unstimulated (middle), stimulated with poly(I:C) (pIC; 1 µg/ml,
6 h; top), or stimulated with LPS (0.3 ng/ml, 6 h; bottom). NES, normalized enrichment score; FDR, false discovery rate. (B) Heat map illustrating the dif-
ferential expression of a set of ISGs in Nfat5+/+ WT and Nfat5−/− KO BMDMs in basal conditions (Unst) or in response to poly(I:C) stimulation (pIC; 0.2 and 1 µg/
ml, 6 h; see Table S1 for an extended list of genes responsive to IFNα and β differentially expressed between poly(I:C)-stimulated wild-type and NFAT5-
deficient BMDMs). Log2 FC, fold-change in log2. (C) RT-qPCR analysis of the indicated ISGs and the NFAT5-induced Il1b in Nfat5+/+ and Nfat5−/− BMDMs in
basal conditions and after 6 h of stimulation with 1 µg/ml of poly(I:C). (D) RT-qPCR analysis of Ifnb1 and the ISGs Ifit2 and Mx1 in Nfat5+/+ and Nfat5−/− BMDCs
differentiated with GM-CSF (GM-BMDCs), and peritoneal macrophages left unstimulated or stimulated with poly(I:C) (1 µg/ml, 6 h). (E) RT-qPCR analysis of
IFN-I genes, ISGs Ifit2 andMx1, and Nfat5 in Nfat5+/+ and Nfat5−/− BMDMs in basal conditions and after 6 h of stimulation with poly(I:C), IFNα or Pam3CSK (P3).
(F) mRNA expression of the indicated genes in Nfat5+/+ and Nfat5−/− BMDMs in basal conditions and after stimulation with IFNβ for 2 and 6 h. (G) RT-qPCR
analysis of Ifnb1 mRNA expression in peritoneal macrophages isolated from mice with a conditional deletion of Nfat5 in immune cells (Nfat5fl/fl Vav-Cre) or
control littermates (Nfat5+/+ Vav-Cre) after in vivo poly(I:C) injection (10 mg/kg, 6 h). (H) IFNβ production measured by ELISA in the supernatants of Nfat5+/+
and Nfat5−/− BMDMs in basal conditions and after 24 h of poly(I:C) stimulation. (I)Western blot analysis for the indicated proteins in Nfat5+/+ (W) and Nfat5−/−
(K) BMDMs left unstimulated or stimulated with poly(I:C) as indicated. All mRNA values were normalized to L32. Error bars in C–H show the mean ± SEM. Data
in A and B are from three independent experiments, each comparing cells from one NFAT5-deficient mouse and one wild-type littermate. Results in C–F are
from seven (C), five (D), four to five (E), and three (F) independent experiments, each comparing cells from one NFAT5-deficient mouse and one wild-type
littermate. Results in G are from three independent experiments and comprise three untreated wild-type, eight poly(I:C)-treated wild-type, and 10 NFAT5-
deficient mice. Results in H are from two independent experiments, each comparing cells from two NFAT5-deficient mice and two wild-type littermates. The
Western blot in I is representative of two independent experiments (see Fig. S1 E). Statistical significance in C and D was determined with: a one-sample t test
using wild-type cells stimulated with 1 µg/ml poly(I:C) as reference with a value of 1; in E with a one-sample t test for comparisons with the reference sample
and an unpaired t test for comparisons between other samples; and in G and H with an unpaired t test. *, P < 0.05; **, P < 0.01.
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Fig. S2 F). Our previous experiments showed that lack of NFAT5
did not affect IFN-I expression in macrophages stimulated with
IFNα or IFNβ (Fig. 1, E and F), which suggested that NFAT5
would not repress IFN-I expression downstream IFNAR. We
thus assessed whether inhibition of IFN-I expression by NFAT5
in the course of viral infection involved IFNAR signaling. For
this, we compared the induction of Ifnb1 and the α IFNs Ifna1 and
Ifna7 upon VSV infection of wild-type, NFAT5-deficient, IFNAR-
deficient, and double NFAT5- and IFNAR-deficient macro-
phages. We found that IFN-I repression by NFAT5 was mainly
independent of IFNAR early after infection (3 h), whereas at
later time points (24 h), maintenance of enhanced IFN-I induc-
tion in NFAT5-deficient cells was IFNAR dependent (Fig. 3 D).
These experiments indicated that lack of NFAT5 enhanced an
early wave of IFNAR-independent IFN-I production, which then
sustained prolonged IFN-I expression through IFNAR. From this
result, we expected that enhanced IFN-I production in NFAT5-
deficient infected cells would lead to increased expression of
ISGs in nearby noninfected cells through paracrine IFN-I action.
To test this, we infected BMDM with GFP-expressing VSV and
analyzed expression of IFN-I and ISGs in infected (GFP+) and
noninfected (GFP−) cells. We confirmed that NFAT5-deficient
BMDM expressed more IFN-I than wild-type cells, which led
to elevated expression of ISGs Mx1 and Ifit2 in noninfected cells
in cultures of macrophages lacking NFAT5 (Fig. S2 G). Finally, to
exclude a role for NFAT5 in viral replication that could influence
our results, we performed infections using UV-inactivated VSV.
These experiments showed that NFAT5-deficient macrophages
also presented increased IFN-I responses to UV-inactivated VSV
(Fig. 3 E), supporting a role for NFAT5 in restraining the acti-
vation of the IFN-I pathway upon sensing pathogens.
Exacerbated IFN-I response in NFAT5-deficient mouse models
causes enhanced activation of HSCs
One effect of systemic production of IFN-I is the activation of
HSCs. This is one of the many effects that infection causes in
the immune system, and it can be readily analyzed upon acute
poly(I:C) treatment of mice, which is the model of choice for
studying IFN-I–mediated HSC activation (Essers et al., 2009;
Pietras et al., 2014; Sato et al., 2009). Poly(I:C) injection in-
duced an early accumulation of IFNα in serum that was more
pronounced in mice deficient for NFAT5 in immune cells
(Nfat5fl/fl Vav-Cre; Fig. 4 A) or myeloid cells (Nfat5fl/fl LysM-
Cre; Fig. 4 B). Acute poly(I:C) treatment consisted of two
consecutive poly(I:C) injections 48 h apart, and short-term
effects were analyzed 24 h later, as in Essers et al. (2009),
Pietras et al. (2014), and Sato et al. (2009). While mice re-
sponded with blood cytopenia, thrombocytopenia, and bone
marrow aplasia, only the bone marrow cellularity was more
affected in Nfat5fl/fl LysM-Cre mice compared with wild-type
mice (Fig. 4 C). Acute poly(I:C) treatment was then used as the
model of systemic IFN-I–mediated HSC activation, which we
measured by analyzing the percentage of bone marrow line-
age− Sca-1+ cKit+ cells (LSK), HSCs (CD150+ CD48− LSK),
multipotent progenitors 3/4 (MPP3/4; CD150− CD48+ LSK),
and MPP2 (CD150+ CD48+ LSK). As expected from their ele-
vated production of IFNα, we detected increased percentages
of LSK, MPP3/4, MPP2, and HSC populations in the bone
Figure 2. Enhanced IFN-I production and viral clearance upon LCMV infection in NFAT5-deficient mouse models. (A and B) Analysis of IFNα con-
centration in serum (A) and viral load in the spleens (B) of Nfat5+/+ Vav-Cre (n = 24) and Nfat5fl/fl Vav-Cre (n = 21) mice 2 d after acute infection with LCMV strain
Docile (2 × 102 PFU per mouse). (C and D)mRNA levels of Ifnb1 and the viral gene LCMV NP in splenic pDCs (C) and peritoneal macrophages (D) of Nfat5+/+ Vav-
Cre (n = 19) and Nfat5fl/fl Vav-Cre (n = 16) mice 2 d after infection. pDCs were isolated by flow cytometry cell sorting using the gating strategy shown in Fig. S2
A. (E–G) Analysis of IFNα concentration in serum (day 2; E), viral load in spleen (day 7; F), and mRNA levels of the viral gene LCMV NP in peritoneal macrophages
(day 7; G) in Nfat5+/+ LysM-Cre (n = 19 in E and G; n = 10 in F) and Nfat5fl/fl LysM-Cre (n = 17 in E and G; n = 10 in F) mice after acute infection with LCMV. Error
bars in A–G show the mean ± SEM. Data in A–D comprise three independent in vivo infection experiments. Data in E–G comprise two independent in vivo
infection experiments. Statistical significance was determined with an unpaired t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 3. NFAT5 represses IFN-I responses in macrophages and DCs infected with different viruses. (A and B) Expression of the mRNA of Ifnb1 and ISGs
Ifit2 andMx1 in NFAT5-deficient (Nfat5−/−) and wild-type (Nfat5+/+) BMDMs (A) and BMDCs differentiated with GM-CSF (GM-BMDCs; B) at different times after
infection with VSV (top) or MCMV (bottom), using a multiplicity of infection (MOI) of 1. mRNA values for each gene were normalized to L32 RNA and are
represented as relative to the 12-h infection time point in wild-type cells. Expression of Nfat5mRNA in wild-type BMDMs is also shown (n = 4). (C)Wild-type
(Nfat5+/+) and NFAT5-deficient (Nfat5−/−) BMDCs differentiated with Flt3L and sorted as pDCs (CD11c+ B220+) were infected with VSV (for 6 h; left) or LCMV
(for 12 h; right) to analyze mRNA levels of Ifnb1, Ifna1, and Ifna7, and the ISG Ifit2. mRNA values for each gene were normalized to L32 RNA and are represented
as relative to infected wild-type cells. (D) Expression levels of the mRNA of Ifnb1, Ifna1, and Ifna7 in wild-type, NFAT5-deficient (Nfat5−/− Vav-Cre), IFNAR-
deficient (Nfat5+/+ Vav-Cre Ifnar1−/−), or NFAT5- and IFNAR-deficient (Nfat5−/− Vav-Cre, Ifnar1−/−) BMDMs at the indicated times after VSV infection at MOI 1.
mRNA values for each gene were normalized to L32 RNA and are represented as relative to VSV-infected wild-type cells. (E) Expression of Ifnb1 and Ifit2mRNA
in Nfat5+/+ and Nfat5−/− BMDMs 12 h after infection with UV-inactivated VSV. Error bars in A–E show the mean ± SEM. Results in A and B are from three
Huerga Encabo et al. Journal of Experimental Medicine 6
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marrow of poly(I:C)-treated, NFAT5-deficient mice (Fig. 4, D
and top graphs in E; and Fig. S3, A and B). As Sca-1, one of the
markers generally used to identify hematopoietic progenitor
populations, can be induced by IFN-I in other potentially
contaminant cell types, we further confirmed the identity of
HSCs by including the marker ESAM (Ooi et al., 2009; Pietras
et al., 2014), which was highly expressed in HSCs of both
mouse genotypes in basal and poly(I:C) treatment conditions
(Fig. 4 E, middle graphs; and Fig. S3 A). We also observed that
acute poly(I:C) treatment increased the percentage of apo-
ptotic LSK, HSCs, and MPP3/4 cells in NFAT5-deficient, but
not in wild-type, mice (Fig. 4 E, bottom graphs), and reduced
their pool of quiescent (Ki67neg) HSCs (Fig. 4, F and G; and Fig.
S3 C). Here, we noticed that loss of HSC quiescence in NFAT5-
deficient mice occurred in their CD41neg subset (Fig. 4 G),
which has been described to comprise mostly quiescent cells
(Bernitz et al., 2016). Altogether, these results indicated that
systemic acute IFN-I overproduction in NFAT5 mouse models
caused exacerbated HSC activation and compromised viability
of hematopoietic cell precursors. Increased systemic produc-
tion of IFN-I in NFAT5-deficient mice caused enhanced IFNAR
signaling in HSC precursors of these mice, evidenced by in-
creased STAT1 phosphorylation, higher levels of the IFN-
I–inducible receptor Sca-1, and higher expression of other
ISGs (Fig. 4, H and I; and Fig. S3 D). In line with the idea that
exacerbated HSC activation in NFAT5-deficient mice was
caused by their increased production of IFN-I, treatment of
wild-type and Nfat5fl/fl Vav-Cre mice with the same dose of
IFNα (100,000 U/mice) induced the same extent of HSC ac-
tivation and increased proportions of LSK and MPP3/4 in both
types of mice (Fig. S3, E and F). Deletion of IFNAR rescued the
proportions of quiescent HSCs in poly(I:C)-treated mice to the
levels of untreated mice and also abrogated the differences
between Nfat5fl/fl Vav-Cre and wild-type mice (Fig. 4 J), in-
dicating that the main driver of HSC activation upon poly(I:C)
treatment is IFN-I and supporting the role of NFAT5 in the
control of systemic IFN-I–induced HSC activation.
We next analyzed diverse hematological and hematopoietic
parameters in the model of acute LCMV infection. We first
conducted time course experiments in wild-type mice (Fig.
S4, A–C) and chose day 3 after infection for further compar-
ison with NFAT5-deficient mice. As shown above, acute LCMV
infection induced lower systemic IFN-I production than
poly(I:C) (compare wild-type mice in Fig. 2, A and E with
Fig. 4, A and B), and, consistent with this, short-term re-
sponses to LCMV showed milder changes in bone marrow
aplasia (compare wild-type mice in Fig. 4 C with Fig. S4 D).
These parameters were largely similar in myeloid-specific
NFAT5-deficient and control mice (Fig. S4, D and E), but
increased numbers of lineage-negative bone marrow cells and
HSCs were detected in the infected NFAT5-deficient mice
(Fig. S4 E, left). Although differences in hematopoietic pro-
genitors between NFAT5-deficient and wild-type mice were
more modest in the acute LCMV infection model, they were in
line with the effect of poly(I:C) treatment. Cycling HSCs are
sensitive to repetitive treatment with the chemotherapeutic
drug 5-fluorouracil (5-FU; Lerner and Harrison, 1990). To test
whether NFAT5-controlled IFN-I production is a relevant
contributor to limit HSC activation, we primed myeloid-
specific NFAT5-deficient and control mice with poly(I:C)
and subjected them to two rounds of 5-FU treatment 7 d apart,
as in Essers et al. (2009) (Fig. 4 K, left). As predicted from
their reduced proportion of quiescent HSCs after poly(I:C)
treatment (Fig. 4 G), primed Nfat5fl/fl LysM-Cre mice were
more vulnerable to 5-FU–mediated toxicity than littermate
controls (Fig. 4 K, right). Altogether, these findings indicate
that NFAT5 limits systemic IFN-I production by diverse im-
mune cells, and this preserves quiescence of HSCs.
NFAT5 binds to the Ifnb1 promoter and limits recruitment
of IRF3
Our previous results showed that NFAT5 repressed IFN-I ex-
pression induced by poly(I:C) and viruses, but not upon direct
stimulation with IFN-I, and that lack of NFAT5 did not affect
activation of the IFN-I master transcriptional regulator IRF3.
These observations suggested that NFAT5 might act by targeting
IFN-I genes.We first confirmed that the ability of NFAT5 to limit
IFN-I induction required its direct binding to DNA. For this, we
took advantage of NFAT5-deficient MEFs, which express a
shorter form of NFAT5 with an internal deletion that eliminates
the first exon of its Rel-like DNA binding domain (DBD), and
therefore lacks DNA binding capacity but preserves its dimer-
ization domain and the long C-terminal region (ΔDBD NFAT5;
Fig. 5, A and B; López-Rodŕıguez et al., 2004; Stroud et al., 2002).
We observed enhanced induction of Ifnb1 and Ifit2 genes in VSV-
infected, NFAT5-deficient MEFs (ΔDBD NFAT5; Fig. 5 C), indi-
cating that the inhibitory control of NFAT5 in the IFN-I pathway
was mediated by the ability to contact its specific target sites in
DNA. As an approach to identify NFAT5-binding sites in regu-
latory regions of IFN-I genes, we performed whole genome
ultrasequencing of NFAT5-immunoprecipitated chromatin
(ChIP) using unstimulated and poly(I:C)-treated wild-type
and NFAT5-deficient macrophages. We did not detect signif-
icant NFAT5 binding peaks in a broad region spanning the
IFN-I locus in mouse chromosome 4 (not shown). This region
included various Ifna genes and Ifnb1. As the Ifnb1 promoter
contains a clear consensus binding site for NFAT5 (59-AG-
GAAAA-39), for which we already had evidence of NFAT5
independent experiments, each comparing cells from one NFAT5-deficient mouse and one wild-type littermate. Results in C comprise six BMDC cultures of
each genotype for VSV and four for LCMV analyzed in four independent experiments. Results in D comprise six BMDM cultures of each genotype from three
independent experiments. Results in E show the mean ± SEM of five BMDM cultures of wild-type and NFAT5-deficient from three independent experiments.
Statistical significance in A and B was determined with a one-sample t test for comparisons with the reference sample (wild-type cells infected for 12 h) or with
an unpaired t test for comparisons between the other samples. Statistical significance in C was determined with a one-sample t test using infected wild-type
cells as reference. Statistical significance in D and E was determined with an unpaired t test. *, P < 0.05; **, P < 0.01.
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recruitment (see below), we suspected that the ChIP-
sequencing assay was not sufficiently sensitive to detect
some NFAT5-bound regions, as we had already noticed in a
recent work (Buxadé et al., 2018).
We then assessed the binding of NFAT5 to the promoter of
Ifnb1 by quantitative ChIP (qChIP) in poly(I:C)-treated BMDMs.
We used the preimmune sera and NFAT5-deficient cells as
controls for specificity of the NFAT5 ChIP. These experiments
Figure 4. Exacerbated IFN-I response in NFAT5-deficient mouse models causes enhanced activation of HSCs. (A and B) IFNα levels in serum of un-
treated (Untr, n = 3) or poly(I:C)-treated (n = 6–7) mice (pIC; 2.5 mg/kg, 12 h) were measured by ELISA in wild-type and Nfat5fl/fl Vav-Cre (A) or Nfat5fl/fl LysM-
Cre mice (B). Results (mean ± SEM) in A and B are from two independent experiments. N.D., not detected. (C) Number of cells, platelets, and erythrocytes in
whole blood and bone marrow cellularity in wild-type and Nfat5fl/fl LysM-Cre mice left untreated or treated with poly(I:C) (two doses of 2.5 mg/kg of poly(I:C)
administered 48 h apart and analyzed 24 h after the second injection). Bone marrow cell numbers were counted from two femurs and two tibiae per mouse.
Results (mean ± SEM) are from one experiment with five treated and two untreated mice of each genotype. (D) Panels show representative flow cytometry
analysis of hematopoietic progenitor and stem cells within LSK cells in the bone marrow of Nfat5+/+ LysM-Cre and Nfat5fl/fl LysM-Cre mice treated with poly(I:
C) as in C. The gating strategy is shown in Fig. S3 A. (E) The upper panels show the percentages of LSK and the indicated populations within LSK cells in
untreated and poly(I:C)-treated mice, the middle panels show the percentage of ESAM+ cells in the different subsets, and the bottom panels show the
percentage of annexin V+ cells in the indicated subsets. Solid dots represent individual NFAT5-deficient mice, and empty dots are wild-type mice. (F) Rep-
resentative contour plots for cell cycle analysis in HSCs in G. (G) Percentage of quiescent (Ki67neg) HSCs and their CD41+ and CD41neg subsets in wild-type and
NFAT5-deficient mice treated as in C. (H) Phospho-STAT1 (Y701) levels measured by intracellular staining and flow cytometry in LSK cells of untreated Nfat5+/+
Vav-Cre (wild-type) mice (n = 3), and poly(I:C)-treated (2.5 mg/kg, 16 h) Nfat5+/+ Vav-Cre (n = 4) and Nfat5fl/fl Vav-Cre (n = 4) mice. MFI, median fluorescence
intensity. (I) Sca-1 levels measured by flow cytometry in HSCs from top panel in E. Error bars in E and G–I show the mean ± SEM. Results for hematopoietic
subsets analysis in E, Ki67 analysis in whole HSCs in G, and Sca-1 MFI in I are from two independent experiments, with a total of 3–4 untreated mice of each
genotype, 12 poly(I:C)-treated Nfat5+/+ LysM-Cre mice, and 11 poly(I:C)-treated Nfat5fl/fl LysM-Cre mice. Results for ESAM, annexin V, and CD41 analyses in E
and G are from one experiment with two untreated mice of each genotype, and five wild-type and six NFAT5-deficient poly(I:C)-treated mice. Results for
phospho-STAT1 in H are from two independent experiments. (J) Percentage of HSCs in the indicated cell cycle phases after poly(I:C) treatment as in C in wild-
type (three untreated, six treated), NFAT5-deficient (Nfat5fl/fl Vav-Cre, n = 4), IFNAR-deficient (Nfat5+/+ Vav-Cre, Ifnar1−/−, n = 6), or NFAT5- and IFNAR-
deficient mice (Nfat5fl/fl Vav-Cre, Ifnar1−/−, n = 4). Results (mean ± SEM) are from four independent experiments with one to two mice of each genotype per
condition and experiment. Statistical significance in A–J was determined with an unpaired t test. *, P < 0.05; **, P < 0.01. ** in J is for the difference between
wild-type and NFAT5-deficient HSCs in the percentage of cells in G0 and G1 upon poly(I:C) treatment in vivo. (K) Schematic diagram of the poly(I:C) con-
ditioning and 5-FU challenge experiment (left), and Kaplan-Meier representation (right) of survival of Nfat5+/+ LysM-Cre (WT) and Nfat5fl/fl LysM-Cre (KO) mice
under this protocol (13 WT mice treated with 5-FU without poly(I:C) conditioning, 14 WT mice treated with 5-FU after poly(I:C), 12 knockout mice treated with
5-FU without poly(I:C), and 12 knockout mice treated with 5-FU after poly(I:C)). Results are from two independent experiments. Statistical significance in K was
determined with a Mantel-Cox test. ***, P < 0.001.
Figure 5. Repression of IFN-I responses by NFAT5 requires its DBD. (A) Nfat5−/− MEF express a spliced mRNA that lacks a region comprising the DNA-
binding residues in the first exon of its DBD (ΔDBD NFAT5) but preserves the dimerization and C-terminal domains. Results show the mean ± SEM of the four
independent experiments shown in C. (B) Western blot with an antibody that recognizes a C-terminal peptide of NFAT5 shows that Nfat5−/− MEF produce a
shorter NFAT5 protein (ΔDBD NFAT5) due to the lack of a portion of the DBD, but maintains an in-frame C-terminal domain. Results are from two independent
pairs (#1 and #2) of WT and Nfat5−/− (ΔDBD NFAT5) MEF. Tubulin expression was used as a loading control. (C) RT-qPCR analysis of Ifnb1 and Ifit2 mRNA
expression 6 h after VSV infection of wild-type and Nfat5−/− (ΔDBD NFAT5) MEF. mRNA values for each gene were normalized to L32 RNA and are represented
as relative to MOI 1-infected wild-type MEF. Results show the mean ± SEM of four independently performed experiments. Statistical significance was de-
termined with a one-sample t test for comparisons with the reference sample (MOI 1-infected wild-type MEF) or with an unpaired t test for comparisons
between the other samples. *, P < 0.05; **, P < 0.01.
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showed that NFAT5 was recruited to Ifnb1 promoter in response
to poly(I:C) stimulation (Fig. 6 A). Since the Ifnb1 promoter is
centrally regulated by recruitment of transcription factors p65/
NF-κB and IRF3 and histone acetylation (Agalioti et al., 2000;
Honda et al., 2006), we asked whether these parameters were
altered in NFAT5-deficient macrophages. NFAT5-deficient cells
had lower levels of acetylated histone H4 (H4ac) than wild-type
cells in the Ifnb1 promoter in unstimulated conditions but in-
creased them upon poly(I:C) stimulation above the levels of
wild-type cells (Fig. 6 B). We also found that NFAT5-deficient
BMDMs showed reduced p65/NF-κB recruitment but enhanced
IRF3 recruitment to the Ifnb1 promoter upon poly(I:C) stimula-
tion (Fig. 6 C). Our finding of enhanced IRF3 recruitment to the
Ifnb1 promoter in NFAT5-deficient cells paralleled by increased
H4ac levels is consistent with earlier works showing that IRF3
reduces histone density and enhances histone acetylation in the
Ifnb1 promoter upon stimulation (Sato et al., 1998; Yoneyama
et al., 1998; Agalioti et al., 2000). Altogether, our results sug-
gested that Ifnb1 transcription in NFAT5-deficient macrophages
became mainly controlled by IRF3 rather than NF-κB, and in-
dicated that binding of IRF3 to the Ifnb1 promoter could be a
central target of the inhibitory function of NFAT5.
Figure 6. NFAT5 binds to the Ifnb1 promoter and limits recruitment of IRF3. (A) ChIP and quantitative PCR (qChIP) analysis of NFAT5 binding to the Ifnb1
promoter in NFAT5-deficient (Nfat5−/−) and wild-type (Nfat5+/+) BMDMs left untreated (−) or stimulated with poly(I:C) (+; 1 µg/ml, 2.5 h). (B) qChIP analysis of
H4ac and total H4 in the Ifnb1 promoter in untreated or poly(I:C)-treated Nfat5−/− and Nfat5+/+ BMDMs. (C) qChIP analysis of p65 and IRF3 recruitment to the
Ifnb1 promoter in untreated or poly(I:C)-treated Nfat5−/− and Nfat5+/+ BMDMs. Results show the mean ± SEM of six BMDM cultures of each genotype analyzed
in four independent experiments in A; three independent experiments in B, each with cells from one NFAT5-deficient mouse and one wild-type littermate; and
five to six BMDM cultures of each genotype analyzed in C from three independent (p65) and four independent (IRF3) experiments. Statistical significance was
determined with an unpaired t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (D) Alignment of the IFNB1 gene promoter regions in different mammalian species.
Alignment of the indicated genomic regions was done with Jalview. The positions of IRF-binding sites PRDIII and PRDI and the NF-κB–binding site PRDII are
marked with colored boxes. The NFAT5 consensus binding motif is shown in red letters. The position of a conserved NFAT5 consensus binding site that
partially overlaps with PRDIII is indicated with red boxes. The NFAT5-binding site in PRDIII is lost in opossum and sheep but is found further downstream in
PRDI (59-TGGAAA-39; marked with small red boxes). The transcription start sites (TSS) in human and mouse genomes are indicated. The position of the TSS in
human IFNB1 in current databases has been updated with respect to the position originally used in the IFNB1 promoter reporter in Fig. 7.
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Repression of the IFNB1 promoter by NFAT5 is mediated by an
evolutionarily conserved NFAT-IRF overlapping site
The core structure of elements regulating Ifnb1 expression is well
conserved between the proximal mouse and human gene pro-
moters, and indeed this homology extends to the genomes of
other mammal species (Fig. 6 D). Elements displaying a strong
degree of conservation across multiple species include the sites
bound by IRF (PRDIII and PRDI) and NF-κB (PRDII) transcription
factors (Honda et al., 2006; Levy et al., 2011; Panne et al., 2007),
and also a clear NFAT5-binding consensus (59-AGGAAAA-39)
that partly overlaps with the IRF site in PRDIII (Fig. 6 D). We
therefore used a reporter of the minimal human IFNβ promoter
(IFNB1-Luc) to ask whether the activity of this region was under
the control of NFAT5. We observed that inhibition of NFAT5
expression (shNFAT5; Fig. 7 C) doubled the poly(I:C)-induced
activation of the IFNB1-Luc reporter (Fig. 7 A, left panel), indi-
cating that this short region of the IFNB1 promoter was the target
of NFAT5. In this regard, and also in line with our observations
with ΔDBD NFAT5 MEFs (Fig. 5), overexpression of the isolated
NFAT5-DBD (López-Rodŕıguez et al., 2001) reduced the activity
of the IFNB1 promoter (Fig. 7 A, right), again indicating that
NFAT5 limited IFNB1 transcription through its ability to bind
DNA. Reporters driven by specific IRF or NF-κB elements in the
IFNB1 promoter (3× PRDIII-I or 2× PRDII, respectively; Escalante
et al., 2002, 2007) showed that suppressing NFAT5 significantly
increased the poly(I:C)-induced activity of the IRF-regulated 3×
PRDIII-I, but not that of the NF-κB-regulated 2× PRDII (Fig. 7 B).
This finding pointed to IRF elements as the target of the inhib-
itory control of NFAT5. Seeing that there is a consensus NFAT5-
binding sequence partially overlapping the key IRF-binding site
of PRDIII (Fig. 6 D), one possibility consistent with our qChIP
results (Fig. 6, A–C) is that binding of NFAT5 to this region of the
IFNB1 promoter could limit the accessibility of IRF3, the master
regulator of IFN-I expression. We therefore introduced muta-
tions in IFNB1-Luc that specifically targeted nucleotides required
for NFAT5, IRF, or NF-κB binding (Fig. 7 D).While disrupting the
NFAT5 site (Lopez-Rodŕıguez et al., 1999; −91G→A) nearly
doubled the poly(I:C)-induced activity of this reporter, mutation
of either of the two IRF-binding sites (−83GA→CT in PRDIII
or −70GA→CT in PRDI) or the NF-κB binding element
(−56CC→TT in PRDII; Escalante et al., 2002, 2007) impaired its
activation (Fig. 7 E). This effect was quite pronounced for the
PRDIII mutation, which lost responsiveness to poly(I:C), high-
lighting the central role of this element in the control of IFNB1.
We also verified that mutation of the NFAT5 site (−91G→A)
rendered the IFNB1-Luc reporter insensitive to overactivation by
shNFAT5 (Fig. 7 F), indicating that this was the DNA element
mediating the inhibitory effect of NFAT5. In this regard, while
mutation of the consensus binding site of NFAT5 could increase
the residual poly(I:C)-induced activity of the reporters carrying
the PRDI or the PRDII mutants, it did not rescue any activity
from the PRDIII mutant (Fig. 7 G), further supporting that partial
overlap between the IRF and NFAT5 sites in PRDIII could be the
mechanism that balances IFNβ expression. By contrast, the role
of NF-κB in the regulation of IFNB1 transcription was discon-
nected from the NFAT5-IRF competition as its mutant not only
conserved responsiveness of the IFNB1 promoter to poly(I:C), but
also its NFAT5-dependent repression (Fig. 7 G, right). These
reporter assays are consistent with the result that enhanced IRF3
recruitment to the Ifnb1 promoter in NFAT5-deficient macro-
phages sufficed to increase IFNβ expression despite reduced
binding of p65. Altogether, analysis of the mechanism by which
NFAT5-deficient cells enhance IFNβ expression indicates that
they use a transcription factor complex whose components
differ from those used by wild-type cells.
Our findings with the different PRDIII mutants point to a
competition between IRF3 and NFAT5 for binding to this ele-
ment. We addressed this possibility using a cell-free protein–
DNA binding assay (Fig. 7 H). First, we confirmed the direct
binding of NFAT5-DBD to a PRDIII oligonucleotide probe, but
not to a probe mutated in the key NFAT5 site required for re-
pression of the IFNB1 promoter (−91G→A; Fig. 7, D, E, and H).
Binding of NFAT5 to PRDIII was inhibited by the DBD of IRF3
and IRF7, but not by a mutant IRF3 DBD that does not bind DNA
(Fig. 7 H; Escalante et al., 2007). Together with our previous
results, the experiments showing that NFAT5 and IRFs can
displace each other at the PRDIII element illustrate a mechanism
at the genomic level that limits IFNB1 transcription through a
dual NFAT5–IRF-controlled site embedded in its enhanceosome.
Discussion
Here, we show that the transcription factor NFAT5, an inducer
of inflammatory responses inmacrophages, is also a repressor of
IFN-I expression. We found that a key IRF3-dependent activator
element in the IFNB1 enhanceosome contains an overlapping
binding site for NFAT5, which opposes IRF3 and thus balances
IFNβ expression. This genomic arrangement has been main-
tained through the evolution of mammals, yet the existence of a
hidden NFAT5-negative regulatory element within was not
suspected. Our results show that the opposition between NFAT5
and IRF3 in the IFNB1 enhanceosome controls the expression of
IFN-Is and their ISG targets in different types of cells. NFAT5
limits the magnitude of IFN-I response in vivo and has a sig-
nificant impact on both antiviral defense and maintenance of
HSC quiescence.
NFAT5 occupies a distinct functional niche in the control of
antipathogen responses by attenuating IFN-I gene induction
while enhancing expression of other inflammatory mediators
(Buxadé et al., 2012; Tellechea et al., 2018). This unique duality
is the result of the mechanism through which NFAT5 inhibits
IFN-I expression by opposing IRF3, the master transcription
factor specialized in IFN-I expression. This mode of action dif-
fers from known factors that attenuate IFN-I expression. ATF3 is
considered a general repressor of macrophage inflammatory
responses, as it not only inhibits Ifnb1 transcription but also
multiple other inflammatory genes, including Nos2, Tnf, Il6, and
Il12b (Labzin et al., 2015; Gilchrist et al., 2006). IRF2 represses
IFN-I in virus-infected fibroblasts by preventing the recruit-
ment of transcription coactivators to the IFNB1 enhanceosome
(Matsuyama et al., 1993; Senger et al., 2000), but then it pro-
motes TLR3 expression in macrophages so that the net effect of
IRF2 in poly(I:C)-stimulated macrophages is to enhance IFNβ
production (Nhu et al., 2006). Unlike ATF3, NFAT5 is not a
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general inhibitor of inflammatory genes, as it enhances TLR-
induced expression of pro-inflammatory genes unrelated to
IFN-I, such as Nos2, Tnf, Il6, and Il12b (Buxadé et al., 2012;
Tellechea et al., 2018), and in contrast to IRF2, NFAT5 represses
Ifnb1 in fibroblasts as well as in macrophages and DCs, both in
response to viral infection and TLR3 stimulation without af-
fecting TLR3 expression.
Our results point to an evolutionarily conserved mechanism
by which NFAT5 could limit IFN-I responses by attenuating the
expression of both IFNβ and IFNα. IFNβ is a main point of
control of the IFN-I pathway in macrophages and myeloid DCs
due to its ability to enhance expression of several IFNα forms
through a positive feedback via IFNAR signaling and induction
of IRF7 (Honda and Taniguchi, 2006; Marié et al., 1998). Our
finding that IFNβ is a direct target repressed by NFAT5 in
macrophages suggests that the impact of NFAT5 on IFNα could
be a consequence of its primary effect on IFNβ. This reasoning is
also supported by our finding that NFAT5 did not affect the
magnitude of Ifna1 and Ifna7 induction when macrophages were
stimulated with exogenous IFNα or IFNβ instead of TLR ligands.
However, we also observed that lack of NFAT5 caused a mild
increase in the short-term induction of Ifna1 during VSV infec-
tion in IFNAR-deficient macrophages, which would be inde-
pendent of prior IFNβ signaling. This observation raises the
question of whether NFAT5 might directly repress the expres-
sion of some Ifna genes in specific stimulatory contexts. In this
regard, and similarly to what we have observed in the IFNB1
promoter (Fig. 6 D), we noticed that the virus-responsive ele-
ments of genes encoding for several IFNα forms in humans and
mice (Chen et al., 2004; van Pesch et al., 2004) contain an
NFAT5 consensus motif (59-T/AGGAAA-39; Lopez-Rodŕıguez
et al., 1999) overlapping IRF-binding sites. Also, while induc-
tion of IFNα in macrophages and myeloid DCs depends on IFNβ-
mediated activation of IRF7, pDCs express IRF7 constitutively
(Honda et al., 2005), and this allows them to produce IFNα in-
dependently of IFNAR feedback (Barchet et al., 2002). Our
finding that NFAT5-deficient pDCs expressed three- to fivefold
more Ifnb1, Ifna1, and Ifna7 than wild-type cells upon viral in-
fection suggests the possibility, supported by our in vitro com-
petition assays, that NFAT5 could also regulate expression of
diverse IFN-I by opposing IRF7.
While our results show that NFAT5 opposes IRFs and at-
tenuates IFN-I induction in macrophages and DCs, a recent
work has shown that the calcineurin-activated NFATC3 en-
hances the IRF7-dependent activation of Ifnb1 and Ifna4 pro-
moters in pDCs (Bao et al., 2016). Bao et al. (2016) also found
that deletion of NFATC3 in human pDCs partially impaired the
recruitment of IRF7 to the Ifnb1 promoter and showed that
NFATC3 could bind an Ifnb1 promoter oligonucleotide span-
ning the PRDIII, I, and II motifs that contains the GGAAA
NFAT-binding site. These findings and our results suggest
that IFN-I production in pDCs could be regulated under dif-
ferent stimulatory inputs through a balance between NFAT5
and NFATC3 and their respective abilities to oppose or coop-
erate with IRF proteins. While both NFAT5 and NFATC3
recognize GGAAA elements, NFAT5 differs from calcineurin-
regulated NFATC factors in that it binds DNA as a constitutive
dimer that encircles its target site, whereas NFATC proteins
bind DNA as monomers and can partner with Fos and Jun
proteins, which NFAT5 does not (Lopez-Rodrı́guez et al., 1999;
López-Rodrı́guez et al., 2001; Stroud et al., 2002). It is possible
that the bulkier NFAT5 dimer could hinder the recruitment of
IRFs to the PRDIII element whereas monomeric NFATC3
would permit it and even favor it. This possibility could be
assessed through structural analysis and modeling the effect
of NFAT5 and NFATC3 on the binding of IRFs to the PRDIII
site. Finally, another implication of the NFAT5-IRF competi-
tion mechanism is that IRF target genes whose promoters
lacked a specific configuration of overlapping NFAT5-IRF sites
would not be repressed by NFAT5. Further research will be
needed to test this possibility by identifying IRF3-dependent
genes repressed or unaffected by NFAT5.
Figure 7. Repression of the IFNB1 promoter by NFAT5 is mediated by an overlapping NFAT-IRF site. (A) Activity of a luciferase reporter driven by the
human IFNB1 promoter (IFNB1-Luc) in unstimulated or poly(I:C)-stimulated (6 h) RAW 264.7 macrophage cells transfected with shNFAT5 or shGFP (left), or with
plasmids encoding the DBD of NFAT5 fused to GFP (NFAT5-DBD) or GFP alone (right). (B) Activity of the 3× PRDIII-I Luc (left) and 2× PRDII-Luc (right) reporters
in unstimulated or poly(I:C)-stimulated (6 h) RAW 264.7 cells transfected with shNFAT5 or shGFP. (C) Western blot of NFAT5 in poly(I:C)-treated RAW 264.7
cells transfected with shGFP or shNFAT5. (D)Mutagenesis strategy to target the consensus binding sites for NFAT5, IRF3 (PRDIII and PRDI), and NF-κB (PRDII)
in the IFNB1 enhanceosome. (E–G) Activity of the corresponding IFNB1-Luc reporter mutants. In all experiments, luciferase activity was normalized for the
efficiency of electroporation using a Renilla-expressing plasmid cotransfected in the same cells. Normalized luciferase units in each experiment are shown
relative to a reference sample (with value 100) of cells transfected with control shGFP plasmid or GFP-encoding plasmid and stimulated with 10 µg/ml poly(I:
C). Error bars in A, B, and E–G show the mean ± SEM. Results in A are from 10 independent transfection experiments in the left panel and 3 in the right panel.
Results in B are from six independent transfection experiments in the left panel and four in the right panel. Western blots in C are representative of two
independent experiments. Results in E and G are from six independent transfection experiments and from three independent experiments in F. Statistical
significance was determined with a one-sample t test for comparisons with the reference sample or with an unpaired t test for comparisons between the other
samples. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (H) Flow cytometry assay to assess the competition between the DBDs of NFAT5 and IRF proteins at the
PRDIII element of the IFNB1 enhanceosome. The schematic diagram depicts a GST-tagged DBD of NFAT5 (GST–NFAT5-DBD) bound to a biotin-tagged, double-
strand PRDIII oligonucleotide (IFNB1 PRDIII oligo) and captured on glutathione-Sepharose beads. The IFNB1 PRDIII oligo is detected by flow cytometry with
eFluor 450–labeled streptavidin. Competition between IRF and NFAT5 was assessed by preincubating the IFNB1 PRDIII oligo with recombinant IRF-DBD. The
flow cytometry dot plot shows the forward scatter (FSC) and side scatter (SSC) profiles in logarithmic scale (log10) of the glutathione-Sepharose beads, and the
histograms on the right show the eFluor 450 signal on NFAT5-coated beads for a mutant IFNB1 PRDIII oligo with the NFAT5 site disrupted (NFAT5mut oligo,
used to determine the nonspecific binding background), and for the wild-type IFNB1 PRDIII oligo in the absence or presence of competitor IRF3 (wild-type and
DNA binding mutant) and IRF7. The bars show the quantification of the flow cytometry assays. Results are from two independent experiments, each one with
two technical replicates for each binding reaction. Statistical significance was determined with an unpaired t test. **, P < 0.01.
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The functional significance of NFAT5-mediated IFN-I re-
pression connects with its role as inducer of pro-inflammatory
and antipathogen gene expression downstream PRRs (Buxadé
et al., 2012; Tellechea et al., 2018). While evidently playing a
protective role against viruses, IFN-I produced in antiviral re-
sponses canweaken other antipathogenic defenses andmake the
organism vulnerable to bacteria and fungi (Guarda et al., 2011;
Shahangian et al., 2009). Onemechanism bywhich IFN-I does so
is by dampening production of inflammatory cytokines such as
IL-1β in macrophages (Guarda et al., 2011). NFAT5 can enhance
specific antipathogenic responses in TLR-activated macrophages
by promoting expression of pro-inflammatory genes including
Il1b (Buxadé et al., 2012; Tellechea et al., 2018), and this capacity
could be modulated by its ability to repress IFN-I. Elucidating
how NFAT5 affects the interplay between inflammatory and
IFN-I responses during overlapping viral and bacterial in-
fections is an open question for future studies.
While NFAT5-mediated attenuation of IFN-I could reduce the
strength of antiviral responses in the short term, it also helped
maintain HSC quiescence and viability during acute poly(I:C)
treatment. Persistent IFN-I production can lead to exhaustion of
hematopoietic progenitor pools, induce apoptosis in proliferat-
ing HSCs, and promote immunomodulatory mechanisms that
inhibit effector T cell responses in chronic infections (Essers
et al., 2009; Pietras et al., 2014; Ng et al., 2013; Teijaro et al.,
2013). Our results suggest the possibility, which remains to be
explored, that the ability of NFAT5 to reduce IFN-I production
could confer long-term benefits by lessening these detrimental
effects. Ultimately, the ability of NFAT5 to enhance or repress
different antipathogen responses connects with the notion that
the immune system has been tuned through evolution to safely
balance effectiveness of antipathogen responses against their
potential harmful effects to the organism.
Materials and methods
Mice
Nfat5+/− heterozygous mice in a pure 129/sv background were
crossed to obtain Nfat5−/− and Nfat5+/+ littermates as described
(Buxadé et al., 2012). Nfat5-floxed (Nfat5fl/fl) mice in a pure
C57BL/6 background were crossed with LysM-Cre mice to ob-
tain mice lacking Nfat5 in myeloid cells, and with Vav-Cre mice
to obtain mice lacking NFAT5 in immune cell lineages (Buxadé
et al., 2018). LysM-Cre mice were purchased from The Jackson
Laboratory (Cat# 004781), and Vav-Cre mice were kindly pro-
vided by Dr. Thomas Graf (Center for Genomic Regulation,
Barcelona, Spain). Ifnar−/− mice were kept in C57BL/6 back-
ground and were obtained from Manuel Rebelo at the Rodent
Facility of the Gulbenkian Institute (Lisbon, Portugal). Mice
were housed in groups of two to five per cage, containing in-
dividuals of different genotypes, and they were analyzed be-
tween 8 and 16 wk of age. Mice were of the same sex in each
individual experiment, and results were reproduced in inde-
pendent experiments using either female or male mice without
noticeable differences due to gender. Mice were bred and
maintained in specific pathogen–free conditions, and animal
handling and experiments were in accordance with protocols
approved by the ethics committee of the Barcelona Biomedical
Research Park/Universitat Pompeu Fabra Animal Care and Use
Committee, and performed in accordance with the Declaration
of Helsinki and the European Communities Council Directive
(86/609/EEC).
In vivo LCMV infection
8–12-wk-old mice were infected i.p. with a low dose (2 × 102
PFUs) of the strain Docile of LCMV to induce an acute infection.
Mice were maintained under specific pathogen–free conditions
in our in-house facility. Viral titers from the spleens of infected
mice were determined on MC57 cells using the focus-forming
assay as previously described (Battegay et al., 1991). A small
piece of spleenwas collected the day of necropsy and put directly
at −80°C until its use. For the assay, frozen spleens were
smashed, resuspended in DMEM, and serial dilutions were
made. Then, 200 µl of the last three dilutions were placed in a
24-well plate containing 400,000 cells and incubated for 4 h at
37°C. Once the cells formed a monolayer, a 1:1 mixture of 3%
methocel and 2× DMEMwas added into each well and incubated
at 37°C for 48 h. For the staining of PFUs, cells were fixed with
37% formaldehyde, washed twice with PBS, and incubated for
20 min with 1% Triton X-100 (TX-100) solution. For blocking
nonspecific binding, cells were incubated for 1 h at room tem-
perature with PBS containing 10% FCS. Cells were then incu-
bated for 1 h with rat anti-LCMV nucleoprotein antibody VL-4
(Battegay et al., 1991) and for 1 hwith anti-rat IgG HRP secondary
antibody (Jackson ImmunoResearch, Cat# 112–035-003). To vi-
sualize the plaques, DAB Peroxidase Substrate kit (Vector Lab-
oratories, Cat# SK-4100) was used.
In vivo HSC activation and 5-FU challenge
To analyze HSC activation, 8–12-wk-old mice were injected i.p.
with 2.5 mg/kg of poly(I:C) two times, 48 h apart, and analyzed
24 h after the second injection as described previously (Pietras
et al., 2014). Fig. 4, D and F; and Figs. S2, A and B; and S3 A show
the flow cytometry gating strategy for the analysis of diverse
HSPC populations and analysis of Ki67/DAPI staining in HSCs
(Sca-1+ cKit+ CD48− CD150+). 5-FU challenge was performed by
i.p. injections of 150 mg/kg 5-FU at days 1 and 7 after the poly(I:
C) injection, as shown in Fig. 4 K. Activation of HSCs with IFNα
in vivo (24 h) was done by injecting IFNα (100,000 U/mouse;
Miltenyi Biotec, Cat#130-093-131) subcutaneously as previously
described (Essers et al., 2009).
Analysis of hematological parameters
Peripheral blood (150 µl) from the tail vein was collected in
EDTA-coated vials (Microvette; Sarstedt AG & Co., Cat#
20.1288). Blood hematological parameters were measured using
a CVM-Procell hematology blood analyzer.
Cells and viruses
BMDMs were generated as previously described (Buxadé et al.,
2012). Briefly, mice were sacrificed and the femoral and tibial
marrow was flushed from the bone with DMEM supplemented
with 2 mM glutamine, 50 µM β-mercaptoethanol, and 1 mM
sodium pyruvate plus penicillin/streptomycin (incomplete
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medium). Cells were then resuspended in complete DMEM
(incomplete medium supplemented with 10% heat inactivated
FBS) with 25% (volume/volume) L929 supernatant (as the
source of macrophage-CSF) and incubated for 6–7 d in polysty-
rene dishes at 37°C in 5% CO2 atmosphere. For functional assays,
BMDMs were harvested with PBS plus 5 mM EDTA by gentle
pipetting, washed with PBS, and plated (106 cells/3 ml/well) in
tissue culture plates. BMDCs were obtained by culturing bone
marrow cell suspensions in 10% GM-CSF–supplemented me-
dium for 10 d (Buxadé et al., 2018). In addition, Flt3L-induced
conventional and pDCs were generated by culturing bone mar-
row cell suspensions in 200 ng/ml Flt3L (ImmunoTools, Cat#
12343305) for 10 d, after which BMDCs were isolated by flow
cytometry cell sorting into CD11c+ B220− (conventional BMDCs)
and CD11c+ B220+ (plasmacytoid BMDCs). Peritoneal macro-
phages were harvested by two consecutive peritoneal lavages
with 5 ml of ice-cold PBS and then isolated with magnetic beads
coated with anti-CD11b antibody (M1/70.15 hybridoma super-
natant; kindly provided by Dr. Gabriel Gil, Institut Hospital del
Mar d’Investigacions Mèdiques, Barcelona, Spain). pDCs from
spleens (CD11c+ B220+) were obtained by flow cytometry cell
sorting excluding dead cells (DAPI+) and neutrophils (Ly6G+).
pDCs (DAPI− Ly6G− CD11c+ B220+) and macrophages (DAPI−
Ly6G− CD11b+ F4/80+) were also obtained from bone marrow by
flow cytometry cell sorting. HSCs were obtained from the bone
marrow by flow cytometry cell sorting after lineage exclusion
with antibodies against TER119, CD3, B220, CD11b, and Ly6G, and
selection of Sca-1+ cKit+ CD48− CD150+ cells. Gating strategies for
flow cytometry and cell sorting are shown in Figs. S2, A and B,
and S3 A. Primary MEFs from Nfat5+/+ and Nfat5−/− mice have
been described previously (López-Rodŕıguez et al., 2004), and
were cultured in DMEM supplemented with 10% FBS, 10 mM
Hepes, and 2 mM L-glutamine. VSV-GFP and MCMV-GFP were
kindly provided by Dr. Estanislao Nistal-Villán and Dr. Ana
Angulo, respectively. The LCMV strain Docile was from Dr.
Andreas Meyerhans.
Reagents
Poly(I:C) (Cat# tlrl-pic) and Pam3CSK4 (Cat# tlrl-pms) were
from Invivogen; recombinant mouse IFNα4 was purchased from
eBioscience (Cat# 14–8313); recombinant mouse IFNα for in vivo
experiments was from Miltenyi Biotec (Cat# 130-093-131); and
recombinant mouse IFNβ1 was from BioLegend (Cat# 581302).
5-FU (Cat# F6627), formaldehyde, glycine, Trizma base, EDTA,
β-glycerophosphate, PMSF, leupeptin, pepstatin A, aprotinin,
SDS, β-mercaptoethanol, and TX-100 were from Sigma-Aldrich.
Sodium fluoride was from Merck.
RAW 264.7 transfection and reporter assays
RAW 264.7 mouse macrophage cell line was from ATCC and
provided by Dr. Annabel Valledor (Universitat de Barcelona,
Barcelona, Spain). Cells were negative for mycoplasma con-
tamination in routine periodic tests in our laboratory. 10 × 106
RAW 264.7 macrophage cells were transfected by electropora-
tion in 0.4-cm gap cuvettes (Bio-Rad) at 320 V and 975 μF in a
Bio-Rad Gene Pulser. For each transfection, a total of 25 µg of
plasmid DNA was transfected including 8 µg of the indicated
luciferase-expressing plasmids in each case and 2 µg of pRL-TK
(Promega, Cat# E2231) as an internal control for electroporation
efficiency. For shRNA transfection, 15 µg of shNFAT5 or shGFP
(Buxadé et al., 2012) were transfected. For experiments using
IFNB1-Luc or its mutant forms, 8 µg of each reporter plus 2 µg of
pRL-TK were transfected with 15 µg of pBlueScript (Stratagene,
currently available from Addgene, Cat# 212207) as a carrier.
10 µg of NFAT5-DBD–GFP expression plasmid or its control GFP
expression plasmid (López-Rodŕıguez et al., 2001) were trans-
fected together with 5 µg of pBlueScript as a carrier. 18 h after
transfection, RAW 264.7 cells were stimulated with poly(I:C)
for 6 h and then lysed (Passive Lysis Buffer, Promega, Cat#
E1941) to measure luciferase activity using the Renilla Lu-
ciferase Assay System (Promega, Cat# E2810) following manu-
facturer’s instructions.
Reporter plasmids and mutagenesis
The IFNB1-Luc reporter (driven by the proximal 123 bps of hu-
man IFNB1 promoter) was provided by Dr. Angel Corbı́ (Centro
de Investigaciones Biológicas, Consejo Superior de Inves-
tigaciones Cient́ıficas, Madrid, Spain), and the PRDIII-I–Luc and
PRDII-Luc reporters were from Dr. Tom Maniatis (Columbia
University, New York, NY) and Dr. Benjamin tenOever (Icahn
School of Medicine, New York, NY). Mutations in IFNB1-Luc
reporter (see Fig. 7 D for a description of these mutants) were
introduced with the primers listed in Table S3 with the corre-
sponding base pair changes. The protocol was adapted from the
QuikChange Site-Directed Mutagenesis kit (Agilent). Briefly,
mutant strand synthesis reaction was done using Phusion High-
Fidelity DNA Polymerase (New England Biolabs, Cat# M0530S),
followed by the purification of PCR product with QIAquick Gel
Extraction Kit (Qiagen, Cat# 28704) and digestion with DpnI
(Roche, Cat# 10742970001) for 2 h at 37°C. Purified products
were then transformed by a 1-min heat pulse in DH5α-
competent cells and plated to grow overnight in ampicillin-
containing LB agar plates. Clones were validated by Sanger
sequencing (Genomics Facility, Universitat Pompeu Fabra) and
prepared for transfection using the Plasmid Maxi Kit (Qiagen,
Cat# 12163).
mRNA quantification by RT-qPCR
Total RNA from cultured cells was extracted with the High Pure
RNA Isolation System (Roche, Cat# 11828665001), quantified in a
NanoDrop (ND-1000) spectrophotometer and retrotranscribed
to cDNA using a Transcriptor First Strand cDNA synthesis sys-
tem with random primers (Roche, Cat# 04897030001). Total
RNA from in vivo sorted cells was extracted using the RNeasy
Microkit (Qiagen, Cat# 74004), and the RNA was retro-
transcribed using the SuperScript III First-Strand Synthesis
system (Thermo Fisher Scientific, Cat# 18080051). For RT-qPCR,
LightCycler 480 SYBR Green IMaster (Roche, Cat# 4887352001),
LightCycler 480Multiwell Plate (Roche, Cat# 04729749001), and
the LightCycler 480 Real-Time PCR System (Roche) were used
according to the instructions provided by the manufacturers. All
samples were normalized to L32 mRNA levels using the Light-
Cycler Software, version 1.5. Primers used for RT-qPCR analysis
are listed in Table S3.
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Total RNAwas extracted (RNeasyMicrokit; Qiagen, Cat# 74004)
from wild-type and NFAT5-deficient BMDMs left untreated or
treated with poly(I:C) (6 h, 1 or 0.2 µg/ml). For microarray
analysis, amplification, labeling, and hybridizations were per-
formed according to protocol GeneChip WT PLUS Reagent kit
(P/N 703174 Rev. 2) and then hybridized to GeneChip Mouse
Gene 2.0 ST Array (Affymetrix) in a GeneChip Hybridization
Oven 640. Washing and scanning were performed using the
Hybridization Wash and Stain Kit and the GeneChip System of
Affymetrix (GeneChip Fluidics Station 450 and GeneChip
Scanner 3000 7G) according to the Expression Wash, Stain and
Scan User Manual (P/N 702731 Rev. 3). After quality control of
raw data, the background was corrected, quantile was normal-
ized, and data were summarized to a gene-level using the robust
multi-chip average (Irizarry et al., 2003), obtaining a total of
34,390 transcript clusters, excluding controls, which roughly
correspond to genes. NetAffx 33.2 annotations, mouse genome
10 built, were used to summarize data into transcript clusters
and to annotate analyzed data. Linear Models for Microarray
(Smyth, 2004), a moderated t-statistics model, was used for
detecting differentially expressed genes between the conditions.
Correction for multiple comparisons was performed using false
discovery rate (Benjamini and Hochberg, 1995). Genes with
an adjusted P value <0.05 and with an absolute fold-change
value >1.5 were selected as significant. All data analysis was
performed in R (version 3.0.2) with the following packages:
aroma.affymetrix to normalize data (Bengtsson et al., 2008),
Biobase for general data treatment, and Linear Models for Mi-
croarray to perform differentially expressed analysis. GSEA was
used to perform functional analysis (Subramanian et al., 2005;
Mootha et al., 2003). This method links the obtained microarray
expression profile with GSs available in the Molecular Sig-
natures Database. The classical GSEA analysis was performed
with collections Hallmark, C2, C5, and C7, with default param-
eters and permutation on the gene_sets. GSs with a P value
<0.05 and false discovery rate q value <0.25 were selected.
Analysis of the list of significant differentially expressed genes
in the Interferome database v2.01 (Rusinova et al., 2013) was
done by filtering the search criteria to IFN-I, genes responsive to
IFNα, β, or both, and Mus musculus. The Gene Expression Om-
nibus accession no. for the microarray set is GSE124287.
Western blot
106 BMDMswere lysed in 100 µl TX-100 lysis buffer (1% TX-100,
40 mM Hepes, pH 7.4, 120 mM NaCl, 1 mM EDTA, 1 mM PMSF,
5 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mg/ml pepstatin A,
1 mM NaF, 1 mM sodium orthovanadate, 10 mM sodium pyro-
phosphate, and 10 mM β-glycerophosphate). Protein concen-
tration was quantified using the BCA assay (Thermo Fisher
Scientific, Cat# 23227), and lysates were boiled in reducing
Laemmli buffer. Proteins were subjected to SDS-PAGE and
transferred to Protran membranes (Schleicher & Schuell, Cat#
BA83). Membranes were blocked with 5% dry milk or 2.5% BSA
in Tris-buffered saline (TBS) and immunoblotted with specific
primary antibodies in TBS-Tween 0.05%. Antibodies used are
indicated below. Membranes were then washed with TBS-
Tween 0.05% and incubated with anti-rabbit Ig or anti-mouse
Ig peroxidase-conjugated secondary antibody (GE Healthcare).
After washing with TBS-Tween 0.05%, immunoreactive bands
were visualized using enhanced chemiluminescence reagents
(ECL Western Blotting Detection Reagents; Amersham, Cat#
RPN2106). Primary antibodies used were anti-NFAT5 (Affinity
BioReagents, Cat# PA1-123), anti–phospho-Y701-STAT1 (BD Bi-
osciences, Cat# 612132), anti-STAT1 (BD Biosciences, Cat#
610119), anti–phospho-S396-IRF3 (Cell Signaling, Cat# 4947S),
and anti-pyruvate kinase (Abcam, Cat# Ab191). Western blot
quantification was done with ImageJ/Multi Gauge software
(Fujifilm).
ELISA
Cell-free supernatants from BMDM cultures were analyzed for
IFNβ production using the Verikine Mouse IFN Beta ELISA Kit
(PBL, Cat# 42400–1), following the manufacturer’s instructions.
The concentration of IFNα in serum was analyzed using the
Mouse IFN α ELISA Kit (Invitrogen, Cat# BMS6027) according to
the instructions provided by the manufacturer.
ChIP
BMDMs were cultured in 15-cm-diameter polystyrene dishes
(18–20 × 106 cells) and either left untreated or stimulated with
poly(I:C) (1 μg/ml for 2.5 h) before their fixation with 0.75%
formaldehyde for 10 min at room temperature. Formaldehyde
was then quenched with glycine (final concentration 0.26M) for
5 min. After washing the plates twice with cold PBS, cells were
collected with cell scrapers and lysed in 0.5 ml of lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8, 1 mM PMSF, 5 µg/ml
leupeptin/aprotinin, 1 µg/ml pepstatin A, 10 mM NaF, 10 mM
sodium orthovanadate, and 10 mM β-glycerophosphate) for
30 min, rotating at room temperature. Lysates were sonicated
using the Diagenode Bioruptor sonication system (UCD-200TM-
EX). Each sample was divided into two 1.5-ml tubes containing
250 µl of lysate and sonicated for six cycles (30 s on, 30 s off) at
the high power setting to obtain DNA fragments between 500
and 1,000 bp. After sonication, samples were centrifuged to
remove insoluble debris, supernatants were collected, and 5% of
each sample was used to measure chromatin input. The rest of
the sample was diluted 1:10 in ChIP dilution buffer (1% TX-100,
20 mM Tris-HCl, pH 8, 2 mM EDTA, 150 mMNaCl, 1 mM PMSF,
5 µg/ml leupeptin, 5 µg/ml aprotinin, 1 µg/ml pepstatin A,
10 mM NaF, 10 mM sodium orthovanadate, and 10 mM β-glyc-
erophosphate) for immunoprecipitation. Samples were pre-
cleared with protein A Sepharose beads (GE Healthcare, Cat#
17-0780-01) that were previously pre-adsorbed with fish sperm
DNA (Roche, Cat# 11467140001) and BSA (New England Biolabs,
Cat# B9001S) for 1 h at 4°C. Specific antibodies were added to the
lysates after removing the preclearing beads and incubated
overnight at 4°C. Pre-adsorbed protein A Sepharose beads (GE
Healthcare) were then added, incubated for 1 h at 4°C, and then
washed three times with ChIP washing buffer (0.1% SDS, 1% TX-
100, 20 mMTris-HCl, pH 8, 2 mM EDTA, and 150 mMNaCl) and
once with final washing buffer (0.1% SDS, 1% TX-100, 20 mM
Tris-HCl pH 8, 2 mM EDTA, and 500 mM NaCl). To elute the
DNA, beads were gently shaken with 200 µl of elution buffer
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(1% SDS and 100 mM NaHCO3) for 30 min at room temperature.
To reverse the cross-linking, samples were incubated overnight at
65°C. Samples were then incubated with 6 ng/µl RNase (Roche)
for 30 min at 37°C, incubated for 1 h at 50°C after adding 350 µg/
ml of Proteinase K (Roche), and DNA was purified by ethanol
precipitation. Antibodies used for ChIP were the following:
NFAT5 was detected using a mixture of two rabbit polyclonal
antibodies to the amino-terminal region and the DBD region
(Lopez-Rodŕıguez et al., 1999), and preimmune serum served as
control; anti-IRF3 (Santa Cruz Biotechnology, Cat# sc-9082); anti-
p65 (Santa Cruz Biotechnology, Cat# sc-372); anti-histone H4
(Diagenode, Cat# C15410156-50); anti–acetyl-histoneH4 (Millipore,
Cat# 06–866), and rabbit IgG (Santa Cruz Biotechnology, Cat# sc-
2027). ChIP and its inputs were analyzed by RT-qPCR using the
primers listed in Table S3, and the immunoprecipitated DNA from
each sample was normalized to its respective chromatin input.
RT-qPCR analysis was done with LightCycler Software version 1.5.
Flow cytometry
All experiments were analyzed at the Flow Cytometry core fa-
cility of Universitat Pompeu Fabra using the LSRII (BD Bio-
sciences) equipped with a 488-nm laser, a 633-nm laser and a
407-nm laser, or the LSR FORTESSA (BD Biosciences) equipped
with a 488-nm laser, a 561-nm laser, a 633-nm laser, and a 405-
nm laser. For sorting, cell suspensions were filtered through a
35-µm nylon mesh (Falcon, Cat# 352235) and sorted in a BD
FACS ARIA cell sorter equipped with 488-nm, 561-nm, 633-nm,
and 405-nm lasers. For bone marrow precursors and HSC
analysis, femoral and tibial marrowwere flushed from the bones
to enrich for lineage-negative progenitor populations, and bone
marrow cells were first stained with a biotin-conjugated lineage
markers cocktail (CD3, CD11b, B220, Ly6G, and TER119) and
Mouse Hematopoietic Lineage Biotin Panel (eBioscience, Cat#
88–7774-75), followed by depletion with Streptavidin particles
plus - DM (BD Biosciences, Cat# 557812). Exclusion of dead cells
was done by staining with the fluorescent dye DAPI (1 µg/ml; BD
Biosciences, Cat# 564907) and gating out the positive cells. Ap-
optotic cells were detected by flow cytometry after incubation
with 2 µl/ml of Annexin-V-FLUOS (Roche, Cat# 11828681001)
and 1 µg/ml DAPI (BD Biosciences, Cat# 564907) in complete
DMEM after staining with surface marker antibodies. Annexin
V-positive cells were analyzed in the DAPI-negative population.
Flow cytometry antibodies and other reagents (annexin V, DAPI,
and streptavidin) are listed in Table S4. For intracellular staining
of Ki67 or phospho-STAT1, the Foxp3/Transcription factor fix-
ation/permeabilization buffer (eBioscience, Cat# 00–5521) and
permeabilization buffer (eBioscience, Cat# 00–8333-56) were
used following the one-step protocol for intracellular proteins
from eBioscience. All experiments were analyzed with FACS-
Diva version 6.2 software (BD Biosciences). Gating strategies for
flow cytometry and cell sorting are shown in Figs. S2, A and B;
and S3 A.
Analysis of NFAT5-IRF DNA binding competition
Binding assays were done using bacterially produced recombi-
nant DBDs of human NFAT5 (aa 175–471), wild-type IRF3 (aa
1–112), a DNA binding mutant of IRF3 with Ala substitutions in
Arg78 and Arg81, and wild-type IRF7 (aa 1–134). NFAT5-DBDwas
used as a GST-tagged protein (GST–NFAT5-DBD), as we had
previously validated it in in vitro DNA-binding experiments
(Esensten et al., 2005) and having the GST tag was convenient
for the binding assay. The respective IRF DBDswere produced as
6His-tagged proteins, then had the 6His tag removed with
thrombin or PreScission protease, and were purified again. The
respective bacterial expression constructs and purification
methods have been described previously (López-Rodrı́guez
et al., 2001; Escalante et al., 2007). Purified recombinant wild-
type IRF3 and IRF7 DBDs were kindly provided by Dr. Carlos R.
Escalante, and additional wild-type IRF3 and its double mutant
Arg78Ala Arg81Ala DBD were produced at the Biomolecular
Screening & Protein Technologies Unit of the Centre for Ge-
nomic Regulation (Barcelona, Spain). Biotin-tagged (59-end)
double-strand DNA oligonucleotides spanning the PRDIII site,
which contains overlapping binding sequences for NFAT5 and
IRF in the human IFNB1 enhanceosome, were from Integrated
DNA Technologies. A wild-type and a mutant oligonucleotide
probe with the NFAT5-binding site disrupted (NFAT5mut) were
used in the binding assays and are listed in Table S3.
Assays to assess the competition between NFAT5 and IRF3 or
IRF7 for binding to the PRDIII site were done as follows. First,
NFAT5-DBD (GST–NFAT5-DBD, 1.4 µg per binding reaction, in a
final volume of 20 µl) was incubated with poly(dI):poly(dC) (20
µg/ml) for 60 min at 4°C in binding buffer (5% glycerol, 10 mM
Hepes, 100 mM NaCl, 0.8 mg/ml BSA, and 1 mM dithiothreitol,
pH 7.3) to prevent nonspecific binding to the oligonucleotide
probe. Biotin-tagged double-strand DNA oligonucleotides (oli-
gonucleotide probe) were then added to the reaction (0.8 µg of
oligonucleotide probe per reaction) and further incubated for
90 min at 30°C, plus 30 min at 25°C. Reactions were tested with
different molar ratios of NFAT5-DBD to oligonucleotide probe
(from 1:30 to 1:1), and a ratio of 1:6 for GST–NFAT5-DBD to oli-
gonucleotide probe was selected as it yielded an optimal binding
signal. Then, GST–NFAT5-DBD was captured with glutathione-
Sepharose 4B beads (GE Healthcare, Cat# 17-0756-01) added to
the reaction and incubated for 60 min at 4°C. The equivalent of
0.2 µl of bead slurry was used per sample, and beads were
previously filtered (Filcon 70-µm filters, BD Biosciences, Cat#
340606) to remove large particles that could obstruct the cy-
tometer. Beads with captured NFAT5-DNA complexes were then
washed with binding buffer to remove unbound biotin-ds-oligo,
resuspended in 100 µl of binding buffer and incubated with 3 µg
of streptavidin conjugated with eFluor 450 (eBioscience, Cat#
48-4317-82) for 30 min at 4°C. Beads were then washed twice
with PBS, resuspended in 300 µl of PBS, and transferred to flow
cytometer tubes for analysis. For competition assays between
NFAT5-DBD and IRF-DBDs, the biotin-ds-oligowas preincubated
with the respective IRFs for 45 min at 30°C before adding
NFAT5-DBD to the binding reaction. IRF-DBDs were used in a 4:
1 molar excess with respect to NFAT5-DBD.
Sequence alignment
Jalview (Waterhouse et al., 2009) was used for alignment of the
IFNB1 promoter region in the genomes of different mammalian
species.
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All data are presented as mean ± SEM. Data were analyzed with
GraphPad Prism 6 software. Normality (Gaussian distribution)
of samples was determined by a D’Agostino-Pearson normality
test before calculating statistical significance with an unpaired
t test (for sets of samples with a Gaussian distribution) orMann-
Whitney test (samples with a non-Gaussian distribution). A one-
sample t test was used when samples were compared with a
reference control sample (set to an arbitrary value of 1 or 100).
Specific statistics analyses, number of samples, and independent
experiments done are indicated in each respective figure legend.
Online supplemental material
Fig. S1 (related to Fig. 1) includes the following bioinformatics
analysis of the microarray data: GSEA analysis of the IFNγ and
apoptosis responses, and a volcano plot with all the ISG genes
differentially expressed between poly(I:C)-treated NFAT5-
deficient and control macrophages. It also illustrates the ex-
pression of NFAT5 upon poly(I:C) and IFNα treatments, and
analysis of STAT1 expression and phosphorylation (Y701) in
wild-type and NFAT5-deficient BMDMs. Fig. S2 (related to Figs.
2 and 3) illustrates the gating strategies used to isolate pDCs and
macrophages from spleens and bone marrow of LCMV-infected
mice, and includes a panel showing that infected NFAT5-
deficient and control mice have similar numbers of diverse in-
nate immunity cells. This figure also describes the expression of
a group of ISGs in pDCs and macrophages from NFAT5-deficient
and control mice 3 d after in vivo LCMV infection. Fig. S2 in-
cludes the expression of IFN-I–related genes in in vitro–infected
NFAT5-deficient and control conventional DCs and also shows
cell-intrinsic and paracrine effects of the NFAT5-mediated IFN-I
repression upon infection. Fig. S3 (related to Fig. 4) illustrates
the flow cytometry gating strategy used to analyze percentages
of the HSPC and HSC cycle profile and shows the percentages of
NFAT5-deficient LSK and MPP3/4 and proportion of quiescent
Ki67-negative HSCs in NFAT5-deficient mice in response to
poly(I:C) and IFNα. This figure also shows the expression of ISG
in HSCs from myeloid-specific NFAT5-deficient mice. Fig. S4
(related to Fig. 4) shows hematologic and bone marrow pro-
genitor cell parameters in wild-type and NFAT5-deficient mice
upon acute LCMV infection. Table S1 shows the list of Interfer-
ome database genes differentially expressed between poly(I:C)-
treated wild-type and NFAT5-deficient macrophages. Table S2
shows comparable expression of genes encoding for components
of TLR and IFN-I signaling in wild-type and NFAT5-deficient
macrophages. Table S3 is a list of primers and oligonucleotide
probes used in this work. Table S4 lists antibodies and reagents
used for flow cytometry and cell isolation.
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